Impact of Levothyroxine on Bone Density in Postmenopausal Women
Author Information
Author(s): Mohammadi Babak, Haghpanah Vahid, Tavangar Seyed Mohammad, Larijani Bagher
Primary Institution: Endocrinology and Metabolism Research Center (EMRC), Tehran University of Medical Sciences, Tehran, Iran
Hypothesis
When should bone mass density be tested in postmenopausal women after the initiation of suppressive levothyroxine therapy?
Conclusion
It seems reasonable to check bone mass density at the 6th month of therapy.
Supporting Evidence
- The study found a maximum speed of bone loss around the 6th month after starting levothyroxine therapy.
- Four cubic polynomial equations were used to model bone mass density changes.
- Bone density measurements can help predict fracture risk in postmenopausal women.
Takeaway
This study looks at how a medicine called levothyroxine affects the bones of older women, suggesting that checking their bone health after six months of treatment is a good idea.
Methodology
The study used data from literature and statistical analyses to model bone mass density changes over time in postmenopausal women receiving levothyroxine therapy.
Potential Biases
Potential biases may arise from the selection of studies and data used for modeling.
Limitations
The study is based on existing literature and may not account for all variables affecting bone density.
Participant Demographics
Postmenopausal women, average age 63.4 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website